公开(公告)号：WO2023083868A1

公开(公告)日：2023-05-19

申请号：PCT/EP2022/081274

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： SAHIN, Ugur ,  HASSAN, Hariz Iskandar Bin ,  STROBL, Stefan ,  RÖSEMANN, Roman

IPC: A61K31/4745 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/395 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.

公开(公告)号：WO2023081441A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/049091

申请日：2022-11-07

Applicant: VENTUS THERAPEUTICS U.S., INC. ,  BEVERIDGE, Ramsay ,  BURCH, Jason ,  FADER, Lee ,  BOILY, Marc-Olivier ,  ST-ONGE, Miguel ,  DORICH, Stéphane ,  CHAGNON, Felix ,  DURET, Guillaume

Inventor： BEVERIDGE, Ramsay ,  BURCH, Jason ,  FADER, Lee ,  BOILY, Marc-Olivier ,  ST-ONGE, Miguel ,  DORICH, Stéphane ,  CHAGNON, Felix ,  DURET, Guillaume

IPC: C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61K31/433 ,  A61K31/506 ,  A61K31/437 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/4439 ,  A61K31/519 ,  A61K31/501 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/536

Abstract: The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof, in the treatment of cGAS-related diseases and disorders.

公开(公告)号：WO2023067058A1

公开(公告)日：2023-04-27

申请号：PCT/EP2022/079200

申请日：2022-10-20

Applicant: QUEEN MARY UNIVERSITY OF LONDON

Inventor： CUTILLAS, Pedro Rodriguez ,  CASADO-IZQUIERDO, Pedro Maria ,  PEDICONA, Federico ,  HIJAZI, Maruan

IPC: A61K31/167 ,  A61K31/203 ,  A61K31/4745 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/706 ,  A61K31/7076 ,  A61K45/06 ,  A61P35/00

Abstract: The invention relates generally to cancer treatments involving an epigenetic agent which promotes the effectiveness of a kinase inhibitor.

公开(公告)号：WO2023064857A1

公开(公告)日：2023-04-20

申请号：PCT/US2022/078048

申请日：2022-10-13

Applicant: INCYTE CORPORATION

Inventor： YE, Qinda ,  MCCAMMANT, Matthew ,  POLICARPO, Rocco ,  SHVARTSBART, Artem ,  ZHU, Wenyu ,  ROACH, Jeremy ,  HOANG, Gia ,  HU, Bin ,  LI, Gencheng ,  SUSICK, Robert ,  POLAM, Padmaja ,  ZHANG, Fenglei ,  QI, Chao ,  WANG, Xiaozhao ,  YAO, Wenqing ,  SOKOLSKY, Alexander ,  YIN, Haolin ,  ZHAO, Le ,  CARLSEN, Peter

IPC: A61P35/00 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/4745

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

公开(公告)号：WO2023062354A2

公开(公告)日：2023-04-20

申请号：PCT/GB2022/052570

申请日：2022-10-11

Applicant: NEWIMMUNE II, LLC

Inventor： HORSBURGH, Brian ,  MOODY, Mark David

IPC: A61K9/00 ,  A61K9/127 ,  A61P35/00 ,  A61P35/04 ,  A61K31/4745 ,  A61K38/20 ,  A61K45/06 ,  A61K47/69

Abstract: The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.

公开(公告)号：WO2023061393A1

公开(公告)日：2023-04-20

申请号：PCT/CN2022/124787

申请日：2022-10-12

Applicant: 昆山新蕴达生物科技有限公司

Inventor： 柯天一 ,  檀琳 ,  温佰刚 ,  劳芳 ,  刘岩 ,  王宁霞 ,  居尚 ,  崔冬雪 ,  杜旭召 ,  欧阳芳幸

IPC: A61K31/4745 ,  A61K9/16 ,  A61K9/10 ,  A61K9/19 ,  A61K47/28 ,  A61K47/14 ,  A61K47/42 ,  A61K47/26 ,  A61P35/00

Abstract: 一种包含7-乙基-10-羟基喜树碱的组合物及其制备方法和用途，所述组合物包含SN-38、脂质、白蛋白和Span 20。

公开(公告)号：WO2023059867A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/046018

申请日：2022-10-07

Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： THAMBISETTY, Madhav ,  GOROSPE, Myriam ,  ANERILLAS, Carlos

IPC: A61K31/18 ,  A61K31/4706 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/506 ,  A61K31/575 ,  A61P25/28 ,  A61K31/7024 ,  A61K31/428

Abstract: A subject is administered an amount of an active agent effective to at least partially normalize an aberrant level of one or more indicators of Alzheimer's disease pathology in the brain, wherein the indicators comprise extracellular amyloid beta concentration, tau phosphorylation, neuroinflammation in the brain, or any combination thereof. The subject may be diagnosed with Alzheimer's disease or may be identified as being at risk of developing Alzheimer's disease.

公开(公告)号：WO2023056716A1

公开(公告)日：2023-04-13

申请号：PCT/CN2021/142943

申请日：2021-12-30

Applicant: 苏州大学

Inventor： 王建南 ,  孟令鹏 ,  戴梦男 ,  裔洪根

IPC: A61L27/22 ,  A61L27/16 ,  A61L27/18 ,  A61L27/50 ,  A61L27/54 ,  A61L27/56 ,  A61K47/42 ,  A61K31/4745 ,  A61P29/00 ,  A61P35/00 ,  B82Y5/00 ,  B82Y40/00 ,  C07C319/14 ,  C07C321/14 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/602 ,  A61L2400/12 ,  A61L27/227

Abstract: 本发明提供了一种丝素蛋白复合多孔支架的制备方法，包括：将家蚕蚕丝脱胶、溶解、透析、过滤、浓缩得到丝素蛋白溶解液；将两端带有羧基的酮缩硫醇用交联剂活化，再与SF溶解液混合反应，将反应后的溶液加入无水乙醇和聚乙烯醇的混合体系搅拌、冷冻、解冻、离心，最后将沉淀物冷冻干燥即得SF/TK纳米粒子；将制备的SF/TK纳米粒子重悬于透析后的SF溶液，加入交联剂反应，然后冷冻干燥得到丝素蛋白复合多孔支架。本发明开发了一类具备智能响应递送药物和生物活性因子的功能SF组织工程支架，提升了药物在病变组织部位治疗的精确性和高效性。

公开(公告)号：WO2023048506A1

公开(公告)日：2023-03-30

申请号：PCT/KR2022/014279

申请日：2022-09-23

Applicant: 국립암센터 ,  주식회사 뉴캔서큐어바이오

Inventor： 김수열

IPC: A61K31/4439 ,  A61K31/4745 ,  A61K31/337 ,  A61K31/7068 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00

Abstract: 본 발명은 카르니틴 아실카르니틴 운반자(Carnitine Acylcarnitine Carrier: CAC) 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물, 및 항암보조제에 관한 것이다. 본 발명의 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 조성물은 카르니틴 아실카르니틴 운반자 억제제 또는 항암제를 각각 단독으로 사용하는 경우에 비하여 다양한 암세포 성장을 유의적으로 감소시켰을 뿐만 아니라, 이종이식 종양 동물 모델에서도 카르니틴 아실카르니틴 운반자 억제제 및 항암제 병용투여에 따른 항암 시너지 효과를 확인하였다. 따라서, 본 발명의 조성물은 효과적인 병용 항암제로 유용하게 활용될 수 있다.

公开(公告)号：WO2023046307A1

公开(公告)日：2023-03-30

申请号：PCT/EP2021/076515

申请日：2021-09-27

Applicant: ISOFOL MEDICAL AB

Inventor： TELL, Roger Ingvar ,  SKINTEMO, Lisa Katarina ,  HOLMÉN, Per Emil Jonathan ,  LINDBERG, Per Lennart

IPC: A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61P35/00

Abstract: The present invention relates to the treatment of right-sided colorectal cancer in human populations having a high frequency of poor prognostic factors, including BRAF- and KRAS mutations, which involves administering multiple boluses of [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF) in connection with 5-fluorouracil (5-FU) based chemotherapy.